SEC Form 4 · accession 0001387131-16-003930

Ohr Pharmaceutical Inc · OHRP

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Executive Officer · Director

Period of report

Jan 19, 2016

Accepted (ET)

Jan 20, 2016 · 10:33 am EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001173281

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock, par value $0.0001 per share	Jan 19, 2016	P	100	$3.92	A	859,604	D
Common Stock, par value $0.0001 per share	Jan 19, 2016	P	200	$3.88	A	859,804	D
Common Stock, par value $0.0001 per share	Jan 19, 2016	P	500	$3.81	A	860,304	D
Common Stock, par value $0.0001 per share	Jan 19, 2016	P	400	$3.75	A	860,704	D
Common Stock, par value $0.0001 per share	Jan 19, 2016	P	200	$3.73	A	860,904	D
Common Stock, par value $0.0001 per share	Jan 19, 2016	P	100	$3.70	A	861,004	D
Common Stock, par value $0.0001 per share	Jan 19, 2016	P	200	$3.67	A	861,204	D
Common Stock, par value $0.0001 per share	Jan 19, 2016	P	200	$3.66	A	861,404	D
Common Stock, par value $0.0001 per share	Jan 19, 2016	P	200	$3.65	A	861,604	D
Common Stock, par value $0.0001 per share	Jan 19, 2016	P	200	$3.60	A	861,804	D
Common Stock, par value $0.0001 per share	Jan 19, 2016	P	400	$3.59	A	862,204	D
Common Stock, par value $0.0001 per share	Jan 19, 2016	P	100	$3.57	A	862,304	D
Common Stock, par value $0.0001 per share	Jan 19, 2016	P	100	$3.56	A	862,404	D
Common Stock, par value $0.0001 per share	Jan 19, 2016	P	850	$3.55	A	863,254	D
Common Stock, par value $0.0001 per share	Jan 19, 2016	P	1,200	$3.54	A	864,454	D
Common Stock, par value $0.0001 per share	Jan 19, 2016	P	1,000	$3.53	A	865,454	D
Common Stock, par value $0.0001 per share	Jan 19, 2016	P	100	$3.522	A	865,554	D
Common Stock, par value $0.0001 per share	Jan 19, 2016	P	200	$3.52	A	865,754	D
Common Stock, par value $0.0001 per share^F1	holding	—	—		—	697,865	I	By SKS Ocular 1 LLC

No Table II lines on this filing.

F1SKS Ocular I LLC directly owns the shares of Common Stock. On May 30, 2014, the Issuer completed an ophthalmology assets acquisition of SKS Ocular LLC and SKS Ocular I LLC. Pursuant to the acquisition agreement, among other things, SKS Ocular I LLC is eligible to receive additional shares of Common Stock in three contingent milestone payments. Milestone 1 has been met and on December 15, 2015, the Issuer issued 497,859 shares of Common Stock to SKS Ocular I LLC. The Reporting Person has investment and voting power with respect to the Common Stock held by SKS Ocular 1 LLC. Therefore, the Reporting Person may be deemed to beneficially own the shares of Common Stock beneficially owned by SKS Ocular 1 LLC. The Reporting Person disclaims any beneficial ownership of the Common Stock directly owed by SKS Ocular I LLC except to the extent of his pecuniary interest therein.